Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
BNTC
#3000
Benitec Biopharma Inc. Common Stock
13.250
0
USD
+10.42%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+10.42%
Changement Mensuel
+11.72%
Evolution sur 6 mois
-20.23%
Changement Annuel
-20.23%
Clôture Précédente
12.000
0
Open
13.250
0
Bid
Ask
Low
13.250
0
High
13.250
0
Volume
30
Marchés
Actions des Marchés US
Soins de Santé
BNTC
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
480.69 K
480.69 K
2.55 M
10.56 M
26.25 M
—
Valuation ratios
Enterprise value
14.96 M
5.42 M
7.85 M
25.81 M
209.39 M
1.09 B
Price to earnings ratio
—
-0.52
-0.29
-1.32
-11.14
-59.98
Price to sales ratio
—
129.85
74.92
—
611.33
—
Price to cash flow ratio
—
-0.6
-0.31
-1.52
-17.96
-75.98
Price to book ratio
—
3.29
27.82
0.62
4.35
7.43
Enterprise value to EBITDA ratio
-1.12
-0.31
-0.41
-1.15
-5.11
-29.05
Profitability ratios
Return on assets %
-0.65
-3.05
-4.38
-0.42
-0.38
-0.33
Return on equity %
-0.69
-6.32
-96.84
-0.46
-0.39
-0.35
Return on invested capital %
-4 480.64
-3 514.23
-2 167.37
-2 657.75
65 K
—
Gross margin %
100
100
100
—
100
—
Operating margin %
-23.04 K
-24.46 K
-25.44 K
—
-6 026.7
—
EBITDA margin %
-22.65 K
-24.23 K
-25.26 K
—
-5 917.17
—
Net margin %
-23.53 K
-24.94 K
-26.08 K
—
-5 471.43
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
15.05
1.9
0.94
10.49
54.67
184.12
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0.01
0.01
0
0.01
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
-33.08
-13
-4.78
-0.65
-0.44
EBIT per share
—
-37.14
-13.77
-5.54
-1.13
-1.03
EBITDA per share
—
-36.8
-13.67
-5.52
-1.13
-1.03
Total debt per share
—
—
—
—
—
—
Cash per share
—
8.45
1.79
12.53
2.7
11.44
Net current asset value per share
—
10.03
2.69
12.73
2.72
11.5
Tangible book value per share
—
6
0.15
11.64
2.69
11.22
Working capital per share
—
4.76
-0.18
11.51
2.67
11.17
Book value per share
—
6
0.15
11.64
2.69
11.22
Nouvelles
L’action Benitec BioPharma conserve sa recommandation d’achat suite à des données d’essai positives
Benitec BioPharma stock maintains Buy rating on positive trial data
Benitec présente des résultats intermédiaires d’un essai de thérapie génique
Benitec reports interim results from gene therapy trial
Benitec BioPharma : notation maintenue après données sur thérapie génique
Benitec BioPharma stock rating maintained on gene therapy data
Benitec présentera les résultats de l’étude sur la thérapie génique BB-301 en mars
Benitec to present BB-301 gene therapy study results in March
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Citizens maintient sa note "Market Outperform" sur l’action Benitec BioPharma
Citizens reiterates Market Outperform rating on Benitec BioPharma stock
Benitec BioPharma maintient sa note d’achat chez TD Cowen grâce à de solides données sur l’OPMD